Managers / Q2 2022 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Summary
Sivik Global Healthcare LLC reported $176M in U.S.-listed holdings across 38 positions for Q2 2022.
Its largest position, UNH, represents 4.5% of the portfolio.
Compared with Q1 2022, the fund opened 2 new positions and exited 13.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 91.3% · $161M
- ADR · 6.6% · $12M
- ETP · 2.1% · $4M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SNYSanofi | NEW | +75.0K | 75.0K | +$4M | $4M |
| AAgilent Technologies Inc | NEW | +30.0K | 30.0K | +$4M | $4M |
| LLYEli Lilly & Co | ADDED | +11.5K | 21.5K | +$4M | $7M |
| CVSCVS Health Corp | SOLD OUT | −60.0K | 0 | −$6M | $0 |
| Laboratory Corp of America Ho | SOLD OUT | −20.0K | 0 | −$5M | $0 |
| GMEDGlobus Medical Inc | SOLD OUT | −65.0K | 0 | −$5M | $0 |
| CYHCommunity Health Systems Inc | SOLD OUT | −300.0K | 0 | −$4M | $0 |
| AMEDAmedisys Inc | SOLD OUT | −20.0K | 0 | −$3M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | UNHUnitedHealth Group Inchistory → | Cash Securities | 4.52% | $8M | 15.5K |
| 2 | MCKMcKesson Corphistory → | Cash Securities | 4.17% | $7M | 22.5K |
| 3 | HUMHumana Inchistory → | Cash Securities | 4.12% | $7M | 15.5K |
| 4 | ELVElevance Health Inchistory → | Cash Securities | 4.11% | $7M | 15.0K |
| 5 | LLYEli Lilly & Cohistory → | Cash Securities | 3.96% | $7M | 21.5K |
| 6 | BSXBoston Scientific Corphistory → | Cash Securities | 3.92% | $7M | 185.0K |
| 7 | TMOThermo Fisher Scientific Inchistory → | Cash Securities | 3.86% | $7M | 12.5K |
| 8 | NVONovo Nordisk A/Shistory → | Cash Securities | 3.80% | $7M | 60.0K |
| 9 | DHRDanaher Corphistory → | Cash Securities | 3.75% | $7M | 26.0K |
| 10 | CICigna Corphistory → | Cash Securities | 3.74% | $7M | 25.0K |
| 11 | CNCCentene Corphistory → | Cash Securities | 3.61% | $6M | 75.0K |
| 12 | SYKStryker Corphistory → | Cash Securities | 3.45% | $6M | 30.5K |
| 13 | CORAmerisourceBergen Corphistory → | Cash Securities | 3.22% | $6M | 40.0K |
| 14 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 2.98% | $5M | 50.0K |
| 15 | UHSUniversal Health Services Inchistory → | Cash Securities | 2.72% | $5M | 47.5K |
| 16 | ACHCAcadia Healthcare Co Inchistory → | Cash Securities | 2.69% | $5M | 70.0K |
| 17 | HCAHCA Healthcare Inchistory → | Cash Securities | 2.63% | $5M | 27.5K |
| 18 | JNJJohnson & Johnsonhistory → | Cash Securities | 2.52% | $4M | 25.0K |
| 19 | ABTAbbott Laboratorieshistory → | Cash Securities | 2.47% | $4M | 40.0K |
| 20 | BAXBaxter International Inchistory → | Cash Securities | 2.37% | $4M | 65.0K |
| 21 | ISRGIntuitive Surgical Inchistory → | Cash Securities | 2.28% | $4M | 20.0K |
| 22 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 2.24% | $4M | 47.5K |
| 23 | IQVIQVIA Holdings Inchistory → | Cash Securities | 2.16% | $4M | 17.5K |
| 24 | SNYSanofihistory → | Cash Securities | 2.13% | $4M | 75.0K |
| 25 | XBISPDR S&P Biotech ETFhistory → | Cash Securities | 2.11% | $4M | 50.0K |
| 26 | THCTenet Healthcare Corphistory → | Cash Securities | 2.09% | $4M | 70.0K |
| 27 | EHCEncompass Health Corphistory → | Cash Securities | 2.07% | $4M | 65.0K |
| 28 | MDTMedtronic PLChistory → | Cash Securities | 2.04% | $4M | 40.0K |
| 29 | AAgilent Technologies Inchistory → | Cash Securities | 2.02% | $4M | 30.0K |
| 30 | Charles River Laboratories In | Cash Securities | 1.82% | $3M | 15.0K |
| 31 | LHC Group Inc | Cash Securities | 1.77% | $3M | 20.0K |
| 32 | AVTRAvantor Inchistory → | Cash Securities | 1.77% | $3M | 100.0K |
| 33 | OPCHOption Care Health Inchistory → | Cash Securities | 1.58% | $3M | 100.0K |
| 34 | SGRYSurgery Partners Inchistory → | Cash Securities | 1.23% | $2M | 75.1K |
| 35 | S24Select Medical Holdings Corphistory → | Cash Securities | 1.21% | $2M | 90.0K |
| 36 | CAHCardinal Health Inchistory → | Cash Securities | 1.19% | $2M | 40.0K |
| 37 | Seagen Inc | Cash Securities | 1.01% | $2M | 10.0K |
| 38 | GRFSGrifols SA | Cash Securities | 0.68% | $1M | 100.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.